These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 21114607)

  • 1. Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial(*).
    Yang W; Chen L; Ji Q; Liu X; Ma J; Tandon N; Bhattacharyya A; Kumar A; Kim KW; Yoon KH; Bech OM; Zychma M
    Diabetes Obes Metab; 2011 Jan; 13(1):81-8. PubMed ID: 21114607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study.
    Nauck M; Frid A; Hermansen K; Thomsen AB; During M; Shah N; Tankova T; Mitha I; Matthews DR
    Diabetes Obes Metab; 2013 Mar; 15(3):204-12. PubMed ID: 22985213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes.
    Garber A; Henry RR; Ratner R; Hale P; Chang CT; Bode B;
    Diabetes Obes Metab; 2011 Apr; 13(4):348-56. PubMed ID: 21205128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU).
    Marre M; Shaw J; Brändle M; Bebakar WM; Kamaruddin NA; Strand J; Zdravkovic M; Le Thi TD; Colagiuri S;
    Diabet Med; 2009 Mar; 26(3):268-78. PubMed ID: 19317822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Nauck M; Frid A; Hermansen K; Shah NS; Tankova T; Mitha IH; Zdravkovic M; Düring M; Matthews DR;
    Diabetes Care; 2009 Jan; 32(1):84-90. PubMed ID: 18931095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial.
    Arechavaleta R; Seck T; Chen Y; Krobot KJ; O'Neill EA; Duran L; Kaufman KD; Williams-Herman D; Goldstein BJ
    Diabetes Obes Metab; 2011 Feb; 13(2):160-8. PubMed ID: 21199268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue.
    Jendle J; Nauck MA; Matthews DR; Frid A; Hermansen K; Düring M; Zdravkovic M; Strauss BJ; Garber AJ;
    Diabetes Obes Metab; 2009 Dec; 11(12):1163-72. PubMed ID: 19930006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
    Ferrannini E; Fonseca V; Zinman B; Matthews D; Ahrén B; Byiers S; Shao Q; Dejager S
    Diabetes Obes Metab; 2009 Feb; 11(2):157-66. PubMed ID: 19125777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial.
    Russell-Jones D; Vaag A; Schmitz O; Sethi BK; Lalic N; Antic S; Zdravkovic M; Ravn GM; Simó R;
    Diabetologia; 2009 Oct; 52(10):2046-55. PubMed ID: 19688338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes.
    Kaku K; Rasmussen MF; Clauson P; Seino Y
    Diabetes Obes Metab; 2010 Apr; 12(4):341-7. PubMed ID: 20380655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States.
    Lee WC; Conner C; Hammer M
    Clin Ther; 2010 Sep; 32(10):1756-67. PubMed ID: 21194600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits.
    Nauck M; Marre M
    Postgrad Med; 2009 May; 121(3):5-15. PubMed ID: 19491535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin.
    Hermansen K; Kolotkin RL; Hammer M; Zdravkovic M; Matthews D
    Prim Care Diabetes; 2010 Jul; 4(2):113-7. PubMed ID: 20444662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial.
    Pratley R; Nauck M; Bailey T; Montanya E; Cuddihy R; Filetti S; Garber A; Thomsen AB; Hartvig H; Davies M;
    Int J Clin Pract; 2011 Apr; 65(4):397-407. PubMed ID: 21355967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.
    Charbonnel B; Steinberg H; Eymard E; Xu L; Thakkar P; Prabhu V; Davies MJ; Engel SS
    Diabetologia; 2013 Jul; 56(7):1503-11. PubMed ID: 23604551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
    Garber A; Henry R; Ratner R; Garcia-Hernandez PA; Rodriguez-Pattzi H; Olvera-Alvarez I; Hale PM; Zdravkovic M; Bode B;
    Lancet; 2009 Feb; 373(9662):473-81. PubMed ID: 18819705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus.
    Davies MJ; Chubb BD; Smith IC; Valentine WJ
    Diabet Med; 2012 Mar; 29(3):313-20. PubMed ID: 21883438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes.
    Nauck MA; Hompesch M; Filipczak R; Le TD; Zdravkovic M; Gumprecht J;
    Exp Clin Endocrinol Diabetes; 2006 Sep; 114(8):417-23. PubMed ID: 17039422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Liraglutide and glimepiride on glycaemic control in type 2 diabetes in the Mexican cohort (LEAD 3)].
    García-Hernández P; Arechavaleta-Granell Mdel R; Yamamoto J; Falahati A; González-Gálvez G;
    Rev Med Inst Mex Seguro Soc; 2010; 48(5):543-8. PubMed ID: 21205505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.